BioSpace News Archive

Smart Immune SAS announced that it has appointed Dr Frederic Lehmann as Chief Medical Officer and Dr Pierre Heimendinger as Chief Technical Officer.

ObsEva SA, a biopharmaceutical company developing novel therapies for women’s health, announced an update on its previously announced restructuring efforts.

Marker Therapeutics, Inc. today announced that the Company has been awarded a $2 million grant from the U.S. Food and Drug Administration (FDA) Orphan Products Grants program to support its Phase 2 ARTEMIS trial of its lead multi-tumor-associated antigen (MultiTAA) T cell product candidate, MT-401, in patients with post-transplant acute myeloid leukemia (AML).

ACELYRIN, INC. today announced a $300 million Series C financing to fund izokibep Phase 3 development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) through anticipated submission of biologic license applications (BLA).

Bausch + Lomb Corporation released a report of survey results from the company’s first annual Visionary Report, which was designed to identify new key insights into the value Americans place on their eyesight, as well as the ‘blind spots’ that may exist in the understanding and awareness of Age-related Macular Degeneration, a leading cause of vision loss for those over age 50 and the leading cause of blindness for the 65+ population.

Lykan Bioscience and RoslinCT, a leader in Contract Development and Manufacturing for cell therapies, announced the formation of its inaugural Scientific Advisory Board (SAB).

Merck (NYSE: MRK), known as MSD outside the United States and Canada , announced that Health Canada has granted approval for KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel discussion at the Cantor Fitzgerald Cell and Genetic Medicines Conference on Thursday, September 15, 2022.

Innovation Pharmaceuticals today updated shareholders on recent progress by BT BeaMedical Technologies Ltd. to advance its new image guided surgical laser platform for treating previously inoperable cases of epilepsy and for enabling new treatment options for cancer cases in multiple specialties.

Elidah Inc., a growing medical solutions company that focuses on delivering FDA-cleared, clinically-proven treatment devices for difficult-to-treat female health urinary conditions announced that it has signed a national agreement with VGM & Associates.